

Ref: FOI/GS/ID 4336

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

30 November 2017

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Non-small Cell Lung Cancer.

1. How many of the following patients (excluding clinical trial patients) are currently being managed by your Health Trust:

All Non-Small Cell Lung Cancer (NSCLC) patients

*Patients with NSCLC Stage IIIB**/IV** (Stage 3b/4)*

2. Of the Stage IIIB/IV NSCLC patients, please state the number of patients currently being treated with the following therapies:

Afatinib (Giotrif)

Ceritinib (Zykadia)

Crizotinib (Xalkori)

Erlotinib (Tarceva)

Gefitinib (Iressa)

Nintedanib + docetaxel

Pemetrexed (Alimta) mono or in combination with carboplatin / cisplatin

Gemcitabine mono or in combination with carboplatin / cisplatin

Atezolizumab (Tecentriq)

Nivolumab (Opdivo)

Pembrolizumab (Keytruda)

Paclitaxel mono or in combination with carboplatin / cisplatin

Doxetaxel mono or in combination with carboplatin / cisplatin

Vinorelbine [or other Vinka alkaloid] mono or in combination with carboplatin / Cisplatin

3. If your trust does not treat Stage IIIB/IV NSCLC patients and you refer your patients to another trust, please state to which trust patients are referred

1.

Patient Type	Total number of patients (treated and not treated)	Number currently treated with any active anti-cancer drug treatment (excl. surgery/ radiotherapy)	Number not treated

		only)	
All Non-Small Cell Lung Cancer (NSCLC) patients	29	2	0
Patients with NSCLC Stage IIIB**/IV** (Stage 3b/4)	18	1	0

2.

Therapy	Number of Stage IIIB/IV NSCLC patients currently treated
Afatinib (Giotrif)	
Ceritinib (Zykadia)	
Crizotinib (Xalkori)	
Erlotinib (Tarceva)	
Gefitinib (Iressa)	
Nintedanib + docetaxel	
Pemetrexed (Alimta) mono or in combination with carboplatin / cisplatin	1
Gemcitabine mono or in combination with carboplatin / cisplatin	
Atezolizumab (Tecentriq)	
Nivolumab (Opdivo)	
Pembrolizumab (Keytruda)	
Paclitaxel mono or in combination with carboplatin / cisplatin	
Doxetaxel mono or in combination with carboplatin / cisplatin	
Vinorelbine [or other Vinka alkaloid] mono or in combination with carboplatin / Cisplatin	

**TNM staging for Stage IIIB NSCLC = Any T, N3, M0 or T4, N2, M0

**TNM staging for Stage IV NSCLC = Any T, any N, M1